Ashok Krishnaswami

Ashok Krishnaswami

Auto-generated profile, based on publicly available information

Ashok Krishnaswami

The Permanente Medical Group, Division of Cardiology Kaiser Permanente San Jose Medical Center San Jose California USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2023 in Circulation
Verified
Journal Article
Open access
ADAbdulla A. Damluji
Abdulla A. Damluji
MAMaha Alfaraidhy
Maha Alfaraidhy
NANoora Alhajri
Noora Alhajri
NRNamit N. Rohant
Namit N. Rohant
MKManish Kumar
Manish Kumar
PGParag Goyal
Parag Goyal
Sarcopenia is the loss of muscle strength, mass, and function, which is often exacerbated by chronic comorbidities including cardiovascular diseases, chronic kidney disease, and cancer. Sarcopenia is associated with faster progression of cardiovascular diseases and higher risk of mortality, falls, and reduced quality of life, particularly among older adults. Although the pathophysiologic mechanisms are complex, the broad underlying cause of sarcopenia includes an imbalance between anabolic and catabolic muscle homeostasis with or without neuronal degeneration. The intrinsic molecular mechanisms of aging, chronic illness, malnutrition, and immobility are associated with the development of sarcopenia. Screening and testing for sarcopenia may be particularly important among those with chronic disease states. Early recognition of sarcopenia is important because it can provide an opportunity for interventions to reverse or delay the progression of muscle disorder, which may ultimately impact cardiovascular outcomes. Relying on body mass index is not useful for screening because many patients will have sarcopenic obesity, a particularly important phenotype among older cardiac patients. In this review, we aimed to: (1) provide a definition of sarcopenia within the context of muscle wasting disorders; (2) summarize the associations between sarcopenia and different cardiovascular diseases; (3) highlight an approach for a diagnostic evaluation; (4) discuss management strategies for sarcopenia; and (5) outline key gaps in knowledge with implications for the future of the field.

1 May 2019 in JACC
Verified
Journal Article
Closed access
AKAshok Krishnaswami
Ashok Krishnaswami
MSMichael A. Steinman
Michael A. Steinman
PGParag Goyal
Parag Goyal
AZAndrew R. Zullo
Andrew R. Zullo
TATimothy S. Anderson
Timothy S. Anderson
JTJennifer Tjia
Jennifer Tjia

1 December 2020 in JACC
Verified
Journal Article
Closed access
AKAshok Krishnaswami
Ashok Krishnaswami
CBCraig Beavers
Craig Beavers
MDMichael P. Dorsch
Michael P. Dorsch
JDJohn A. Dodson
John A. Dodson
RCRuth Masterson Creber
Ruth Masterson Creber
SBSanjeev P. Bhavnani
Sanjeev P. Bhavnani

20 February 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
NINaila Ijaz
Naila Ijaz
YJYasser Jamil
Yasser Jamil
CBCharles H. Brown
Charles H. Brown
AKAshok Krishnaswami
Ashok Krishnaswami
AOAriela R Orkaby
Ariela R Orkaby
ADAbdulla A. Damluji
Abdulla A. Damluji
As the older adult population expands, an increasing number of patients affected by geriatric syndromes are seen by cardiovascular clinicians. One such syndrome that has been associated with poor outcomes is cognitive frailty: the simultaneous presence of cognitive impairment, without evidence of dementia, and physical frailty, which results in decreased cognitive reserve. Driven by common pathophysiologic underpinnings (eg, inflammation and neurohormonal dysregulation), cardiovascular disease, cognitive impairment, and frailty also share the following risk factors: hypertension, diabetes, obesity, sedentary behavior, and tobacco use. Cardiovascular disease has been associated with the onset and progression of cognitive frailty, which may be reversible in early stages, making it essential for clinicians to diagnose the condition in a timely manner and prescribe appropriate interventions. Additional research is required to elucidate the mechanisms underlying the development of cognitive frailty, establish preventive and therapeutic strategies to address the needs of older patients with cardiovascular disease at risk for cognitive frailty, and ultimately facilitate targeted intervention studies.

8 April 2015 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
AKAshok Krishnaswami
Ashok Krishnaswami
CMCharles E. McCulloch
Charles E. McCulloch
MTMagdy Tawadrous
Magdy Tawadrous
JJJames J. Jang
James J. Jang
HLHon Lee
Hon Lee
AGAlan S. Go
Alan S. Go
To determine the relative risks of long-term mortality between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) among patients with end-stage renal disease (ESRD). We identified 1015 patients with ESRD who underwent coronary revascularization between 1996 and 2008 within Kaiser Permanente Northern California. We obtained clinical variables from health plan databases, state death certificates and social security administration files. Our primary and secondary outcomes, respectively, were all-cause mortality and repeat revascularization. Our primary predictor was CABG compared with PCI. We used a Cox proportional hazards model for multivariable analyses. The mean age of CABG and PCI patients was similar (64.7 ± 10.6 and 63.4 ± 9.3, respectively, P = 0.06). The CABG group had a higher proportion of diabetics (P = 0.045), and higher nitrate use (P = 0.01). Adjusted for age, gender, race, year of index revascularization, number of vessels intervened, duration of dialysis and baseline comorbidities, patients referred for CABG during the first year had a hazard ratio (HR) of 1.16 [95% confidence interval (CI), 0.80–1.67] for mortality compared with PCI. During Years 1–5, the HR was 0.91 (95% CI, 0.63–1.33) with an overall HR of 0.73 (95% CI, 0.43–1.22). The sub-HR as calculated by the Fine-Gray competing risk model was 0.51 (95% CI, 0.31–0.85). As there are no randomized clinical trials in this area, our observational study adds to the growing body of literature that suggests a significant decrease in repeat revascularization with CABG and at least equivalency in long-term mortality with CABG when compared with PCI in ESRD patients.

26 May 2021 in The American Journal of Medicine
Verified
Journal Article
Closed access
PGParag Goyal
Parag Goyal
SMSabrina Mangal
Sabrina Mangal
AKAshok Krishnaswami
Ashok Krishnaswami
MRMichael W. Rich
Michael W. Rich